ストックスクリーナーアプリを入手
5.72
5.30%
-0.32
Y Mabs Therapeutics Inc (YMAB) 最新ニュース
Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025 - The Manila Times
Y-mAbs Therapeutics, Inc. to Announce Fourth Quarter and Full Year 2024 Results on March 4, 2025 - Nasdaq
When Will Y-mAbs Report Q4 Earnings? Key Date for Biotech Investors - StockTitan
(YMAB) Trading Signals - Stock Traders Daily
Layoff Tracker: Encoded Lays Off 29% of Employees - BioSpace
YMAB Stock Touches 52-Week Low at $5.69 Amid Market Challenges - MSN
Brain Cancer Market Expected to rise, 2034 | Y-mAbs Therapeutics - openPR
When the Price of (YMAB) Talks, People Listen - Stock Traders Daily
After Falling -15.24% During The Past Week, Should You Still Buy Oruka Therapeutics Inc (NASDAQ: ORKA)? - Marketing Sentinel
Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Stock Has Dropped -21.18% Over The Month – Is There Room For Growth? - Marketing Sentinel
Mineralys Therapeutics Inc (NASDAQ: MLYS): Can The Stock Still Lose Despite An -20.31% YTD Loss? - Marketing Sentinel
Now Is The Time To Build A Position In Health In Tech Inc (NASDAQ:HIT) - Marketing Sentinel
Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel
ScanTech AI Systems Inc (NASDAQ: STAI) Gain Of 9.66% Compared To 52-Week Low; YTD Fall -84.49% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel
Apogee Therapeutics Inc (NASDAQ: APGE) Recovered 16.57% From The 52-Week Low, And Now It’s -12.32% YTD – This Is What You Do Now – Marketing Sentinel - Marketing Sentinel
Now Is The Time To Build A Position In SolarBank Corporation (NASDAQ:SUUN) - Marketing Sentinel
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $20.89 Average Price Target from Analysts - MarketBeat
YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN
Y-Mabs Therapeutics Inc (YMAB) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference - The Manila Times
Cancer Treatment Pioneer Y-mAbs Takes Center Stage at Major Healthcare Conference - StockTitan
Brain Cancer Market Report 2034: Epidemiology Data, Pipeline - openPR
Analytical Overview: Y-Mabs Therapeutics Inc (YMAB)’s Ratios Tell a Financial Story - The Dwinnex
An Overview of Castellum Inc (AMEX: CTM)’s Stock Performance and Outlook - Marketing Sentinel
A stock that deserves closer examination: Y-Mabs Therapeutics Inc (YMAB) - US Post News
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Now Is The Time To Build A Position In Outlook Therapeutics Inc (NASDAQ:OTLK) - Marketing Sentinel
YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
YMAB stock touches 52-week low at $6 amid challenging year - MSN
Jasper Therapeutics Inc (NASDAQ:JSPR) Drops -9.55%, But A Strong Recovery May Be Imminent - Marketing Sentinel
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting - The Manila Times
Groundbreaking Cancer Treatment Data: Y-mAbs' GD2-SADA Shows Remarkable Preclinical Results - StockTitan
Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdles - MSN
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Position Boosted by JPMorgan Chase & Co. - Defense World
Y-mAbs Therapeutics’ SWOT analysis: innovative cancer therapy stock faces growth hurdles - Investing.com Nigeria
(YMAB) Trading Report - Stock Traders Daily
Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials - Seeking Alpha
Cantor Fitzgerald Weighs in on YMAB FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts YMAB FY2025 Earnings - MarketBeat
Contrasting Lotus Pharmaceuticals (OTCMKTS:LTUS) and Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Now Is The Time To Build A Position In Capricor Therapeutics Inc (NASDAQ:CAPR) - Marketing Sentinel
Now Is The Time To Build A Position In NewGenIvf Group Ltd (NASDAQ:NIVF) - Marketing Sentinel
XORTX Therapeutics Inc (NASDAQ:XRTX) Plunging -39.23% In 6 Months – Here’s What To Expect - Marketing Sentinel
Barclays PLC Increases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics Releases Corporate Overview PresentationOn January 13, 2025, Y-mAbs Therapeutics, Inc. disclosed a corporate overview presentation on its investor relations website, https://ir.ymabs.com. The presentation is intended for investor - Defense World
Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Y-mAbs Therapeutics Updates on Business and Clinical Trials - TipRanks
Y-mAbs Therapeutics (NASDAQ:YMAB) Given "Buy" Rating at HC Wainwright - MarketBeat
Y-mAbs Therapeutics Announces Business Realignment Plan and Preliminary 2024 Financial ResultsOn January 6, 2025, Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) revealed a business realignment plan aimed at maximizing operational efficiencies. The p - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns Outperform Rating from Wedbush - Defense World
Y-mAbs Therapeutics Announces Strategic Business Realignment - Yahoo Finance
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):